Infectious Disease Alert – February 1, 2007
February 1, 2007
View Issues
-
Trichomonas Infection — It's Not Just a Girl Thing, But the Guys Don't Know It
Male sexual partners of women with vaginal trichomoniasis were tested, using urethral and urine culture, as well as urine polymerase chain reaction (PCR), for evidence of infection with this flagellated protozoan. -
First Chemokine Receptor Antagonist Available Under Expanded Access
Uk-427,857 (Maraviroc) is an investigational small-molecule HIV entry inhibitor that binds to the CCR5 chemokine receptor on the surface of T-cells. This chemokine receptor is normally the receptor for the chemokines MIP-1 alpha and RANTES. -
Posaconazole Salvage in Invasive Aspergillosis
In a multicenter international open-label study, patients with proven or probable invasive aspergillosis (IA) that was refractory to standard antifungal therapy or who were intolerant to such therapy were treated with posaconazole in a total daily amount of 800 mg administered in divided doses. -
Catheter-Related Bloodstream Infections: Doing the Right Thing Pays Off
Pronovost and colleagues conducted a multi-hospital cohort study aimed at reducing the rate of catheter-related bloodstream infections (CRBSIs) in ICUs. The intervention focused on increasing adherence to evidence-based CDC recommendations for catheter insertion. -
New Oral Treatment for Chronic Hepatitis B: Telbivudine
Treatment of chronic Hepatitis B is directed at suppressing viral replication, reducing hepatitis (necroinflammatory) activity, slowing progression of fibrotic disease, inducing loss of HBeAg with seroconversion to anti-HBe, and rendering patients noninfectious. -
Updates By Carol A. Kemper, MD, FACP
An outbreak of highly drug-resistant S. enterica Serotype Typhimurium which was resistant to all drugs tested was first identified in 2 young boys in 2004 in Minnesota and North Carolina who had been in contact with pet mice. -
Clinical Briefs in Primary Care supplement
-
Pharmacology Watch: Breast Cancer Rates Have Dropped Since WHI of 2002
Herbal Supplements to Treat Vasomotor Symptoms; Bisphosphonates to Treat LBD, After 5 Years?; FDA Actions